TrialHaemophilia : the official journal of the World Federation of Hemophilia2019

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Midori Shima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.